Evidence map›Paper›PMID 39000123›Full record

ArticleInternational journal of molecular sciences2024

Elucidation of the Gemcitabine Transporters of

Nikoleta Iosifidou, Eleni Anagnostopoulou, Maria Botou, Eirini Kalfa, Ekaterini Tatsaki, Stathis Frillingos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. RSC advances · 2025
    Article
  5. The oncobiome; what, so what, now what?Microbiome research reports · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nikoleta IosifidouLaboratory of Biological Chemistry, Department of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece.
Eleni AnagnostopoulouLaboratory of Biological Chemistry, Department of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece.
Maria BotouLaboratory of Biological Chemistry, Department of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece.
Eirini KalfaLaboratory of Biological Chemistry, Department of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece.
Ekaterini TatsakiLaboratory of Biological Chemistry, Department of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0002-3696-5141
Stathis FrillingosLaboratory of Biological Chemistry, Department of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece.

Funding

Greece and EU-European Regional Development Fund MIS 5047236Greece and EU-European Social Fund MIS 5033021
6 · The paper itself

Abstract

Gemcitabine (2',2'-difluoro-2'-deoxycytidine), a widely used anticancer drug, is considered a gold standard in treating aggressive pancreatic cancers. Gamma-proteobacteria that colonize the pancreatic tumors contribute to chemoresistance against gemcitabine by metabolizing the drug to a less active and deaminated form. The gemcitabine transporters of these bacteria are unknown to date. Furthermore, there is no complete knowledge of the gemcitabine transporters in

Indexed as

DeoxycytidineGemcitabineAntimetabolites, AntineoplasticDrug Resistance, BacterialDrug Resistance, NeoplasmEscherichia coli K12Escherichia coli ProteinsGammaproteobacteriaHumansMembrane Transport ProteinsAntimetabolites, AntineoplasticDeoxycytidineEscherichia coli ProteinsGemcitabineMembrane Transport ProteinschemoresistanceEscherichia coli K-12gamma-proteobacteriagemcitabinenucleoside transporters

Identifiers

PMID39000123
PMCPMC11241209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.